Long-term outcomes of incidental prostate cancer at radical cystectomy.


Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
11 2020
Historique:
received: 06 02 2020
revised: 18 04 2020
accepted: 16 05 2020
pubmed: 7 7 2020
medline: 13 8 2021
entrez: 7 7 2020
Statut: ppublish

Résumé

We evaluated the natural history and long-term outcomes of incidentally detected prostate cancer (PCa) at radical cystectomy (RC) for bladder cancer (BCa). We identified 1,640 male patients who underwent RC between 1992 and 2012. Patients were stratified as clinically insignificant and clinically significant PCa, based on Grade Group (GG) 1 and ≥2, respectively. Survival was assessed using the Kaplan-Meier method. There were 329 (20%) patients with incidentally detected PCa at RC: 245 (15%) GG1, 52 (3.2%) GG2, 20 (1.2%) GG3, 6 (0.4%) GG4, and 6 (0.4%) GG5. Median follow-up among survivors was 9.6 years (interquartile range 7.5-13.3), during which time 253 patients died, of whom 127 died of BCa and 1 died of PCa. Nine patients experienced biochemical recurrence (BCR), 4 underwent salvage PCa therapies, and 2 developed PCa metastases. Patients with clinically significant PCa were significantly more likely to experience BCR (6% vs. 1.6%; P = 0.04) and had shorter median time to BCR (1.8 vs. 10.4 years; P = 0.01) than those with clinically insignificant PCa. No patients with BCR had greater than pT2N0 BCa or positive BCa margins. Ten-year PCa-specific survival, BCa-specific survival, other cause-specific survival, and overall survival were 99%, 57%, 63%, and 35%, respectively. In a large RC series, we note a 20% rate of incidental PCa, the majority of which are clinically insignificant. On long-term follow-up, we determined that BCR and PCa mortality are extremely rare events among these patients. Pending validation, future guidelines may consider omission of PCa surveillance for some patients with incidental PCa at RC.

Identifiants

pubmed: 32624422
pii: S1078-1439(20)30222-2
doi: 10.1016/j.urolonc.2020.05.018
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

848.e17-848.e22

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Vignesh T Packiam (VT)

Department of Urology, Mayo Clinic, Rochester, MN.

Matvey Tsivian (M)

Department of Urology, Mayo Clinic, Rochester, MN.

Svetlana Avulova (S)

Department of Urology, Mayo Clinic, Rochester, MN.

Vidit Sharma (V)

Department of Urology, Mayo Clinic, Rochester, MN.

Robert Tarrell (R)

Department of Health Sciences Research, Mayo Clinic, Rochester, MN.

John C Cheville (JC)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

Igor Frank (I)

Department of Urology, Mayo Clinic, Rochester, MN.

R Houston Thompson (RH)

Department of Urology, Mayo Clinic, Rochester, MN.

Matthew K Tollefson (MK)

Department of Urology, Mayo Clinic, Rochester, MN.

Matthew T Gettman (MT)

Department of Urology, Mayo Clinic, Rochester, MN.

R Jeffrey Karnes (RJ)

Department of Urology, Mayo Clinic, Rochester, MN.

Prabin Thapa (P)

Department of Health Sciences Research, Mayo Clinic, Rochester, MN.

Stephen A Boorjian (SA)

Department of Urology, Mayo Clinic, Rochester, MN. Electronic address: Boorjian.stephen@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH